I am newbie here but I think the difference between Pharmaxis and Syntara as companies have to been taken in context and not discuss the MC and SP in isolation.
PXS had a $14 Mn per year drain on the cash while SNT is much leaner, has funded trials, with cash in the bank and more R&D refunds on the way. SNT now is focused on clinical trials and not trying to run a manufacturing plant and managing 75 people. To top that we have 4 clinical trials and 3 papers in Nature, funding from Parkinson’s UK etc., providing external validation.
While in this transformation from caterpillar to butterfly is seen by SHs, outsiders with little knowledge only see a company whose SP has languished for a year, board change. Renaming the company also probably hasn’t helped as people may not follow the new code.
We SHs see all positives from inside-out view and outside-in view probably needs education and change which I think the CEO is working on with multiple stakeholders presentations.
AIMO. No advice.
Add to My Watchlist
What is My Watchlist?
